Thanks for these early replies. Yes, biotech stocks seem to have the same growing pains, needing to raise cash through releasing new shares, sometimes without restrictive covenants. But every once in a while a company will hit the proverbial homerun and that can offset the earlier shareholder losses. I guess timing is everything. It seems to me that now could prove to be a better time for acquiring shares here than having done so a year or two ago (Obviously the shares are lower priced now, but if what I have been researching is correct it seems that the company is transitioning into a more diversified company with greater revenue streams?) I just wrote my friend with my early thoughts and told him I had requested some help from this board. I have turned him onto stocks in the past and he gives me an occasion alert. Maybe I'll try to catch the conference call on the 23rd.
Lee
News 
Market Data 
Discover 
